MX2015012894A - Composiciones y metodos para formulaciones de alfavirus vivos atenuados. - Google Patents

Composiciones y metodos para formulaciones de alfavirus vivos atenuados.

Info

Publication number
MX2015012894A
MX2015012894A MX2015012894A MX2015012894A MX2015012894A MX 2015012894 A MX2015012894 A MX 2015012894A MX 2015012894 A MX2015012894 A MX 2015012894A MX 2015012894 A MX2015012894 A MX 2015012894A MX 2015012894 A MX2015012894 A MX 2015012894A
Authority
MX
Mexico
Prior art keywords
live
compositions
attenuated
methods
attenuated alphavirus
Prior art date
Application number
MX2015012894A
Other languages
English (en)
Other versions
MX361342B (es
Inventor
Dan T Stinchcomb
Jill A Livengood
Laszlo Varga
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50489420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015012894(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of MX2015012894A publication Critical patent/MX2015012894A/es
Publication of MX361342B publication Critical patent/MX361342B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Las modalidades en este documento se refieren a composiciones de y métodos para alfavirus vivos atenuados. En ciertas modalidades, una composición de virus vivo atenuado incluye, pero no se limita a, uno o más alfavirus vivosatenuados y composiciones para reducir la inactivación y/o degradación del alfavirus vivo atenuado. En otras modalidades, la composición de virus vivo atenuado puede ser una composición de vacuna. En otras composiciones, una composición de alfavirus vivo atenuado puede incluir tampón de HEPES. En otras modalidades, el tampón de HEPES puede incluir además un carbohidrato y gelatina y/o una sal.
MX2015012894A 2013-03-14 2014-03-13 Composiciones y metodos para formulaciones de alfavirus vivos atenuados. MX361342B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361784122P 2013-03-14 2013-03-14
PCT/US2014/026570 WO2014151855A1 (en) 2013-03-14 2014-03-13 Compositions and methods for live, attenuated alphavirus formulations

Publications (2)

Publication Number Publication Date
MX2015012894A true MX2015012894A (es) 2016-04-04
MX361342B MX361342B (es) 2018-12-04

Family

ID=50489420

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015012894A MX361342B (es) 2013-03-14 2014-03-13 Composiciones y metodos para formulaciones de alfavirus vivos atenuados.
MX2018014977A MX2018014977A (es) 2013-03-14 2015-09-14 Composiciones y metodos para formulaciones de alfavirus vivos atenuados.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2018014977A MX2018014977A (es) 2013-03-14 2015-09-14 Composiciones y metodos para formulaciones de alfavirus vivos atenuados.

Country Status (20)

Country Link
US (2) US10137186B2 (es)
EP (2) EP3603667A1 (es)
JP (3) JP6426695B2 (es)
KR (1) KR20160003662A (es)
CN (2) CN105377293B (es)
AP (1) AP2015008733A0 (es)
AU (2) AU2014236804B2 (es)
BR (1) BR112015023205A2 (es)
CA (1) CA2903711A1 (es)
CR (1) CR20150553A (es)
DO (1) DOP2015000226A (es)
EC (1) ECSP20007842A (es)
HK (1) HK1220358A1 (es)
MX (2) MX361342B (es)
MY (1) MY178476A (es)
NZ (1) NZ631012A (es)
PH (1) PH12015502115A1 (es)
SG (3) SG10201801459SA (es)
TW (2) TWI649087B (es)
WO (1) WO2014151855A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX361342B (es) 2013-03-14 2018-12-04 Takeda Vaccines Inc Composiciones y metodos para formulaciones de alfavirus vivos atenuados.
US10538785B2 (en) 2013-12-23 2020-01-21 Renaud Vaillant Lyophilized lentiviral vector particles, compositions and methods
KR20180135912A (ko) * 2016-03-31 2018-12-21 다케다 백신즈 인코포레이티드 개선된 제형을 이용한 알파바이러스의 안정화 조성물 및 방법
NL2022538B1 (en) * 2019-02-08 2020-08-19 Academisch Ziekenhuis Groningen Methods for providing purified viral particles of Semliki Forest Virus (SFV), preparations obtainable thereby, and uses thereof.
US20230183657A1 (en) * 2021-01-19 2023-06-15 Nitta Gelatin Inc. Virus stabilizer, gelatin hydrolysate for virus stabilizer, and viruscontaining composition

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338335A (en) * 1980-02-05 1982-07-06 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
RU2035508C1 (ru) * 1991-08-16 1995-05-20 Институт органической химии СО РАН Питательная среда для стабилизации вируса венесуэльского энцефалита лошадей
US5545555A (en) * 1994-07-25 1996-08-13 Microtest, Inc. Microbial transport media
AU4594996A (en) * 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
US6465634B1 (en) * 1996-04-05 2002-10-15 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US6290967B1 (en) * 1996-12-20 2001-09-18 Merck & Co., Inc. Stabilizers for lyophilized vaccines
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
DE19803453A1 (de) * 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
EP1100944A1 (en) * 1998-07-30 2001-05-23 The Johns Hopkins University School Of Medicine Targeted alphavirus and alphaviral vectors
US6869907B2 (en) * 2000-05-02 2005-03-22 Pentax Corporation Color-image-forming medium
FR2814957B1 (fr) * 2000-10-06 2002-12-20 Aventis Pasteur Composition vaccinale et procede de stabilisation
JP4550421B2 (ja) * 2001-12-12 2010-09-22 メイン・ファ−マ・インタ−ナショナル・プロプライエタリ−・リミテッド ウイルスの保存のための組成物
CA2482448C (en) 2002-04-11 2014-07-08 Medimmune Vaccines, Inc. Preservation of bioactive materials by freeze dried foam
WO2005058356A2 (en) 2003-12-17 2005-06-30 Wyeth Methods for porducing storage stable viruses and immunogenic compositions thereof
US8865184B2 (en) * 2006-09-01 2014-10-21 Bharat Biotech International Limited Vaccine for chikungunya virus infection
EP2099485B1 (en) * 2006-11-03 2018-03-21 AlphaVax, Inc. Alphavirus and alphavirus replicon particle formulations and methods
CA2668834C (en) 2006-11-07 2016-10-11 Sanofi Pasteur Biologics Co. Stabilization of vaccines by lyophilization
CN104083757A (zh) 2007-04-06 2014-10-08 武田疫苗公司 用于活的减毒病毒的方法和组合物
CN101835488B (zh) * 2007-09-04 2018-10-26 美国政府(由卫生和人类服务部、疾病控制和预防中心的部长所代表) 轮状病毒的热灭活
SI2198007T1 (en) 2007-09-14 2018-04-30 Sanofi Pasteur Biologics, Llc Pharmaceutical compositions containing Clostridium difficile A and B toxoids
EP3085787B1 (en) 2008-01-24 2020-10-28 The Board of Regents of the University of Texas System Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof
BRPI0923341B8 (pt) * 2008-12-09 2021-05-25 Coley Pharm Group Inc oligonucleotideo imunoestimulador, vacina compreendendo o mesmo e seu uso
JP6073031B2 (ja) * 2009-12-28 2017-02-01 タケダ ヴァクシーンズ， インコーポレイテッド インフルエンザ抗原のエンベロープウイルスベースのウイルス様粒子溶液を安定化させる方法
PL2575873T3 (pl) * 2010-06-01 2016-06-30 Novartis Ag Zatężanie i liofilizacja antygenów szczepionkowych grypy
MX361342B (es) * 2013-03-14 2018-12-04 Takeda Vaccines Inc Composiciones y metodos para formulaciones de alfavirus vivos atenuados.

Also Published As

Publication number Publication date
JP2019031543A (ja) 2019-02-28
PH12015502115B1 (en) 2016-01-25
JP6426695B2 (ja) 2018-11-21
MY178476A (en) 2020-10-14
DOP2015000226A (es) 2016-02-29
US10137186B2 (en) 2018-11-27
AU2014236804A1 (en) 2015-10-01
MX361342B (es) 2018-12-04
US20190134182A1 (en) 2019-05-09
EP3603667A1 (en) 2020-02-05
AU2014236804B2 (en) 2018-12-13
SG11201507462QA (en) 2015-10-29
KR20160003662A (ko) 2016-01-11
SG10201909051QA (en) 2019-11-28
NZ631012A (en) 2017-08-25
HK1220358A1 (zh) 2017-05-05
EP2968515A1 (en) 2016-01-20
MX2018014977A (es) 2022-06-27
CA2903711A1 (en) 2014-09-25
JP2020193231A (ja) 2020-12-03
US20140271715A1 (en) 2014-09-18
US10806781B2 (en) 2020-10-20
WO2014151855A1 (en) 2014-09-25
CN105377293A (zh) 2016-03-02
JP6761015B2 (ja) 2020-09-23
CR20150553A (es) 2015-12-01
TW201900192A (zh) 2019-01-01
JP2016513658A (ja) 2016-05-16
BR112015023205A2 (pt) 2017-07-18
ECSP20007842A (es) 2020-09-30
TW201513875A (zh) 2015-04-16
AP2015008733A0 (en) 2015-09-30
PH12015502115A1 (en) 2016-01-25
AU2018236897B2 (en) 2020-09-10
EP2968515B1 (en) 2019-05-08
SG10201801459SA (en) 2018-03-28
CN111729077A (zh) 2020-10-02
TWI649087B (zh) 2019-02-01
AU2018236897A1 (en) 2018-10-18
CN105377293B (zh) 2020-07-17

Similar Documents

Publication Publication Date Title
ECSP20007842A (es) Composiciones y métodos para formulaciones de alfavirus vivos atenuados
CL2016001547A1 (es) Composiciones para el cuidado oral
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
PH12015502401A1 (en) Compositions and methods for enhancing microbial stability
AU2015296298A8 (en) Flagellin-based agents and uses including effective vaccination
GB2535876A (en) Absorbent clumping animal litter compositions
MX2015012737A (es) Vacunas de virus bovino liquidas estables.
MX2016004556A (es) Composicion de hueso comprimido y metodo para usar la misma.
PH12019501722A1 (en) Compositions and methods for promoting hair growth with mpc1 inhibitors
PH12017500627A1 (en) Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof
PH12018502120A1 (en) Live attenuated alphavirus constructs and methods and uses thereof
MX2016007316A (es) Prevencion de infecciones por staphylococcus aureus mediante vacunas de glucoproteina sintetizadas en escherichia coli.
MX2019010101A (es) Composiciones y metodos para promover el crecimiento del cabello con inhibidores de mpc1.
MX2016012112A (es) Feromona tranquilizadora para gatos.
MX2015006986A (es) Solucion de trombina y metodos de uso de esta.
PH12018502119A1 (en) Compositions and methods for stabilizing alphaviruses with improved formulations
EA201591867A1 (ru) Композиция лютеина, подходящая для составов детского питания
MX2016011572A (es) Composiciones antimicrobianas de acido organico.
MX2017014971A (es) Composiciones de sal mejoradas y metodo de preparacion de las mismas.
IN2014MU00284A (es)
WO2018175580A3 (en) Development of an alternative modified live influenza b virus vaccine
AR095118A1 (es) Un procedimiento de inactivación viral en composición que comprende factor vii
MX2016001694A (es) Formulacion de vacuna de sacarido.
NZ708737A (en) Thrombin solution and methods of use thereof
TH179835A (th) องค์ประกอบและวิธีการสำหรับสูตรตำรับอัลฟาไวรัสซึ่งถูกทำให้อ่อนฤทธิ์ที่มีชีวิต

Legal Events

Date Code Title Description
FG Grant or registration